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Abstract  
Autophagy, or self-eating, is the most extensively studied lysosomal degradation 
pathway for the recycling of obsolete or damaged cytoplasmic materials, including 
proteins and organelles. Although this pathway was initially thought to function as 
trafficking system for ‘in bulk’ degradation by the lysosomes of cytoplasmic material, 
it is now widely appreciated that cargo selection by the autophagic machinery is a 
major process underlying the cytoprotective or –possibly- pro-death functions 
ascribed to this catabolic process. Indeed increasing evidence suggests that in 
mammalian cells the removal of dysfunctional or aged mitochondria occurs through a 
selective degradation pathway known as ‘mitophagy’. Due to the crucial role of 
mitochondria in energy metabolism, redox control and cell survival/death decision, 
deregulated mitophagy can potentially impact a variety of crucial cell autonomous 
and non-autonomous processes. Accumulating evidence indicates that during 
malignant transformation aggressive cancers hijack autophagy to preserve energy 
fitness and to acquire the plasticity required to adapt to the hostile microenvironment. 
However, whether and how mitophagy contributes to carcinogenesis, which 
pathways regulates this process in the cancer cells and how cancer cell-mitophagy 
impacts and modifies the tumor microenvironment and therapeutic responses, remain 
largely unanswered issues. In this review, we discuss novel paradigms and pathways 
regulating mitophagy in mammalian cells and the impact this process might have on 
one of the most dreadful human malignancies, melanoma.  
Keywords: Autophagy, mitophagy, reactive oxygen species, signaling, cancer, 
melanoma, anticancer therapy. 
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1. Autophagy; basic molecular machinery  
Macroautophagy (hereafter referred to as autophagy) is a regulated process of self-
eating by which part of the cytoplasm, including long-lived or unfolded proteins and 
superfluous or damaged organelles, is trafficked through the aid of double-
membraned vesicles, known as autophagosomes, to the lysosomes where cargo is 
degraded. Besides functioning as a key quality control mechanism crucial to control 
organelle number and fitness during homeostasis in all eukaryotic cells, recycling of 
intracellular components via this catabolic process supplies an alternative energy 
resource to survive in conditions of famine or reduced oxygen supply [1]. Although 
autophagy is constitutively active at basal levels sufficient to preserve homeostasis 
and cytoplasmic quality control, it can be stimulated ‘on demand’ whenever cells 
sense nutrient or oxidative stress, organellar damage or loss of proteostasis [1]. 
Stimulation of autophagy under these stress conditions is a pro-survival mechanism, 
although under certain circumstances autophagy may favor cell death [2].    
Autophagy initiates by the formation of an isolation membrane (called 
phagophore), usually formed at the contact sites between the endoplasmic reticulum 
(ER) and mitochondria. Additionally other organelles, like the Golgi apparatus, post-
Golgi compartments, as well as the plasma membrane may provide alternative 
sources [3], although the exact molecular players in phagophore-building and 
membrane trafficking in mammalian cells are only beginning to emerge [4, 5]. The 
isolation membrane is further elongated to form double membrane vesicles, which 
deliver their cargo to the lysosomes for degradation and recycling (schematically 
presented in Fig. 1).  
At the molecular level the different stages of autophagy are spatially and 
hierarchically controlled by a set of autophagy-related genes (Atg), conserved 
between yeasts and mammals [6, 7]. A key regulator of autophagy-initiation in 
mammalian cells is the Unc51-like kinase 1/2 (ULK1/2) complex, containing Atg13, 
Atg101 and FIP200 (focal adhesion kinase family interacting protein of 200 kDa). 
This complex is negatively controlled by the mechanistic target of rapamycin complex 
1 (mTORC1) kinase. mTORC1 activation under nutrient/growth factor-rich conditions 
leads to phosphorylation and inactivation of ULK1/2 and Atg13. Starvation-induced 
activation of AMP-activated protein kinase (AMPK), reactive oxygen species (ROS), 
or rapamycin treatment cause the inactivation of mTORC1, which results in the 
induction of autophagy (Fig. 1). Upon activation, the ULK-complex is involved in 
correctly localizing the class III PI3K (PI3KC3)/Vps34 complex, containing p150, 
Atg14L and Beclin1, which regulates nucleation and assembly of the phagophore 
membrane. The activity of this complex is tightly controlled by positive regulators like 
UVRAG, AMBRA1, Rab5 and BIF1 and negative regulators like Rubicon (Fig.1). 
Beclin 1 in this complex can bind –through agency of its BH3 domain- anti-apoptotic 
BCL2 family members, which can by this mechanism exert a negative control on 
autophagy induction. Upon activation ULK1 phosphorylates AMBRA1, hereby 
releasing the AMBRA1 containing PI3KC3-complex from the microtubules, resulting 
in its relocalization to the ER [6, 7]. Important signaling molecules for the regulation of 
the elongation, shaping, and sealing of the autophagosomal membrane are two-
ubiquitin-like conjugation systems, regulating the formation of the Atg5–Atg12–
Atg16L complex and the phosphatidylethanolamine (PE)-conjugation of the 
microtubules-associated light chain-3 (LC3), which becomes associated to the 
autophagosomes through the entire process serving as a marker for their 
identification (see Fig. 1 for a more extensive description).  
Mature autophagosomes can merge with endocytic vesicles (early or late 
endosomes) to become amphisomes or directly fuse with lysosomes, where the 
cargo is degraded by lysosomal hydrolases. Fusion of the autophagosomes with the 
lysosomes is mediated by Rab7, which promotes microtubule transport and 
Syntaxin17, a SNARE protein that is localized on mature autophagosomes [8]. After 
autophagolysosome formation building blocks are freed into the cytosol and LC3 
located at the cytosolic surface of the autophagosolysosome undergoes Atg4-
mediated decoupling from PE to be recycled.  
Because autophagy is usually activated by cellular stress that may 
concurrently initiate apoptotic cell death, accumulation of autophagosomes is often 
detected in cells committed to die. This has led to the suggestion that autophagy may 
be causative for cell death. However, the occurrence of the so called autophagic cell 
death, i.e. cell death caused by the autophagy genetic machinery, has been 
documented so far during developmental stages/tissues in lower organisms, whereas 
in mammalian cells appears to be limited to selective pathological and/or drug-
induced conditions (for an extensive review see [2]).  
 
2. Mitochondria quality control through mitophagy  
Originally autophagy was thought to be a non-selective, bulk degradation 
pathway to recycle obsolete cytoplasmic materials. However during the last decade 
the selective removal of organelles, lipid droplets, proteins and pathogens has been 
extensively documented [9]. The autophagic process governing the specific removal 
of damaged or superfluous mitochondria is known as mitophagy [10].  
Because of the crucial role of mitochondria in metabolism, Ca2+ signaling and redox 
control and as a signaling hub of a variety of pathways impinging on the cell 
death/survival balance, it is not surprising that the selective removal of damaged or 
excessive mitochondria under homeostatic and stress conditions, has evolved as a 
tightly regulated and selective autophagic process. Besides its developmental role in 
erythrocytes maturation, mitophagy serves as a crucial quality control mechanism. In 
line with this, defective mitochondria clearance is exacerbated in aged cells and 
accumulation of unhealthy mitochondria associates -or is possibly causative- to 
crucial pathological conditions, like neurodegeneration and cancer. 
Just like for autophagy, the molecular players of this selective degradation 
process were first described in yeast. Through a genetic screen for yeast mutants 
defective in mitophagy, Atg32, a protein not involved in other autophagy pathways, 
was identified as prime and selective mitochondrial receptor [11]. Upon induction of 
mitophagy Atg32 is phosphorylated by casein kinase 2 [12] and binds the scaffold 
protein Atg11, which regulates cargo selection during autophagy. The Atg32-Atg11 
complex formation then enables the recruitment of mitochondria to the pahgophore 
assembly site. Although in mammalian cells (as described further), some crucial 
mitochondrial receptors have been recently characterized, the functional homologue 
of the yeast Atg32 has not been identified yet.   
Also the mechanisms allowing the selection and isolation of individual 
mitochondria from the dynamic mitochondrial network and regulating the 
encapsulation of this rather large cargo within the autophagosomes, are not 
completely understood. In both yeast and mammalian cells, mitochondria fission, a 
process regulated by the conserved family of dynamin-related proteins and instigated 
by dissipation of the membrane potential, has been shown to precede mitophagy (for 
an extensive review on mitochondria dynamic and mitophagy, see [13]).  
Interestingly, fragmentation of mitochondria, which likely facilitates their 
engulfment by the autophagosomes but per se is not absolutely required for 
mitophagy, appears to occur at specific subdomains located between the 
endoplasmic reticulum (ER) and the mitochondria. An elegant study in yeast by 
Böckler and Westermann revealed that yeast mutants lacking essential components 
of the endoplasmic reticulum mitochondria encounter structure (ERMES), the ER-
mitochondrial tethering complex, displayed a reduced mitophagy rate while a 
synthetic mitochondria-ER tether rescued these mitophagy defects [14]. Based on 
the major findings of that study, it was suggested that the ER-mitochondria contact 
sites may provide sufficient supply of ER-derived lipids required for the isolation and 
expansion of autophagosomal membrane for the engulfment of an isolated 
mitochondrion, and/or recruit key components of the fission machinery [14, 15]. The 
relevance of ER-mitochondria contact sites in mitophagy is also supported by recent 
studies in mammalian cells. The mitochondria-associated membranes (MAMs), i.e. 
the ER subdomains that physically tether the ER to mitochondria, have been shown 
to define the position of mitochondrial fragmentation that precedes the recruitment 
components of the fission (Drp1) and autophagy machinery, like Atg14 and Atg5 [16, 
17]. All together these evidence strongly indicate that the ER-mitochondria contact 
sites have evolved as a privileged subdomains to coordinate mitochondrial 
morphological changes and fission mechanisms regulating mitophagy in eukaryotic 
cells [18].  
Finally, emerging evidence indicate that mammalian cells dispose of complex 
and redundant signaling mechanisms that prime the mitochondria for selective 
recognition by the autophagic machinery.  
In this review we describe the major pathways governing mitochondria priming 
and pruning in mammalian cells, along with the identified molecular players involved. 
A more detailed overview of these pro-mitophagic molecules is presented in Table 1.  
 
3. Signaling mechanisms in mitochondria priming  
a) The PINK1-PARKIN signaling pathway 
The best characterized signaling mechanism for the priming of mitochondria for 
autophagic removal in mammalian cells is the poly-ubiquitylation of mitochondrial 
proteins mediated by PARKIN. PARKIN (also known as PARK2) is a RING-HECT 
hybrid E3 ubiquitin ligase, which is recruited to the outer mitochondria membrane 
(OMM) upon mitochondrial membrane depolarization or accumulation of unfolded 
proteins in the mitochondrial matrix, through a mechanism requiring PINK1 
(Phosphatase and tensin homolog (PTEN)-induced putative protein kinase 1). 
PINK1 (also known as PARK6) is a kinase with an N-terminal mitochondrial import 
sequence, which under basal conditions results in its import into the mitochondria via 
the TOM (the protein translocase of the outer mitochondrial membrane complex) and 
TIM23 (translocase of inner mitochondrial membrane 23 homolog) complexes. 
Following import in the mitochondria PINK1 is cleaved by mitochondrial processing 
proteases (MPP) in the matrix and by the mitochondrial intramembrane protease 
PARL (mitochondrial inner membrane rhomboid protease presenilin-associated 
rhomboid-like protein) localized in the inner mitochondrial membrane (IMM), hereby 
generating an N-terminal destabilizing amino acid. The cleavage product is 
subsequently translocated from the mitochondria into the cytosol, where it is 
degraded by the proteasome, thus guaranteeing constant low levels of mitochondrial 
PINK1 under basal conditions [19, 20] (Fig. 2). When mitochondrial membrane 
potential is lost or misfolded proteins accumulate in the mitochondrial matrix, PINK1 
is no longer imported into the IMM and mitochondrial matrix and its proteolysis by 
MPPs and PARL is prevented [19, 21] (Fig. 2). This allows PINK1 stabilization, 
autophoshorylation and its dimerization in the OMM [22]. A RNAi screen by Hasson 
and co-workers identified TOMM7 as an essential component of the TOM complex to 
shunt and retain PINK1 on the OMM upon mitochondrial damage [23]. Upon 
stabilization on the OMM, PINK1 recruits PARKIN from the cytosol to the damaged 
mitochondria by phosphorylation of its linker region on T175 and T217 in humans 
[24]. Other proteins that have been reported to mediate the relocation of PARKIN to 
the damaged mitochondria are PINK1-phosphorylated Mfn2 (mitochondrial outer 
membrane guanosine triphosphatase mitofusin 2) [25], BNIP3  (BCL2 and 
adenovirus E1B 19 kDa-interacting protein 3) [26] and BNIP3L/NIX (BNIP3 like 
protein/ NIP3-like protein X) [27] (see below), however the underlying molecular 
mechanisms are not known. Upon recruitment to the mitochondria PARKIN poly-
ubiquitylates several mitochondrial proteins, including VDAC1 (the voltage-
dependent anion channel1) [28], mitochondrial hexokinase I (HKI) [29], Miro1 [30], 
Mfn1 and Mfn2 [31]. The ubiquitylated mitochondrial proteins are subsequently 
degraded by the proteasome or recruit ubiquitin-binding LIR-containing adaptors, like 
p62/SQSTM1 and NBR1, resulting in the clustering of the damaged mitochondria 
around the nucleus and their incorporation into the LC3-containing autophagosomes 
[13]. Indeed, the recruitment of p62/SQSTM1 to poly-ubiquitin-positive clusters of 
mitochondria has been shown to require PARKIN, and to be necessary for the 
complete clearance of unfunctional mitochondria [28]. Although PARKIN-mediated 
ubiquitylation is an important signal tagging mitochondria for degradation, little is 
known about the molecular mechanisms that link autophagic isolation of 
mitochondria, autophagosomal membrane expansion and recognition/encapsulation 
of this rather large cargo. Recently members of the TBC family of RAB GTPases 
deactivators, TBC1D15 and TBC1D17, have been identified as important molecules 
for the proper autophagic encapsulation of mitochondria. During PINK1-PARKIN-
mediated mitophagy TBC1D15 and TBC1D17 act in concert with Fis1 – an OMM 
protein part of the mitochondrial fission machinery along with Mitochondrial fission 
factor(Mff) and Drp1- and LC3 homologue proteins to control autophagosomes 
morphology by coordinating the activity of the small GTPase Rab7, a protein that 
governs autophagosomes biogenesis [32, 33]. Interestingly, Fis1 has been shown to 
interact with ER proteins and to enable the recruitment of the fission machinery at the 
contact sites established between these organelles, where also Drp1 has been 
shown to localize [18, 34].  These studies reinforce the role of the ER-mitochondria 
contact sites as privileged interface orchestrating the morphological (i.e. 
mitochondrial fission/division), structural (i.e. membrane source for encapsulation) 
and functional (recruitment of both fission and autophagy machineries).    
Although PINK1-PARKIN-mediated mitophagy has been studied and 
characterized in various neuronal and non-neuronal cell lines, including cancer cell 
lines, its relevance has been mostly explored as a mechanism implicated in the 
pathogenesis of Parkinson’s disease. PINK1 and PARKIN are frequently found to be 
mutated in familial forms of Parkinson’s disease, thus material derived from those 
patients offers a unique potential to validate the role of PINK1 and PARKIN in ex 
vivo/in vivo situations [35]. Ex vivo evidence for the importance of the PINK1-PARKIN 
system in mitophagy was obtained in fibroblasts derived from patients with PINK1 
mutations, where the recruitment of overexpressed PARKIN to the mitochondria after 
treatment with mitochondrial uncouplers was found to be disturbed [36]. Defects in 
mitochondrial metabolism and morphology have been described in tissue derived 
from patients with PARKIN mutations, although the effect on mitophagy was not 
thoroughly investigated in these studies [37, 38]. However direct evidence for the role 
of the PINK1-PARKIN system in mitophagy under physiological conditions is limited, 
and only one study in the drosophila model system has reported the importance of 
this pathway for mitophagy in vivo, by showing an increased half-life of mitochondrial 
proteins, especially of the respiratory chain components, in parkin mutant flies [39].  
However, also PARKIN/PINK1 -independent mechanisms of mitophagy have been 
described [40], highlighting a certain degree of functional redundancy in the signaling 
mechanisms implicated in this selective degradation process in higher organisms. 
 
b) FUNDC1; a mitochondrial receptor 
Most of the molecules known to function as receptors for selective autophagy 
interact with LC3 and LC3-like proteins, via a LIR. Recently FUNDC1, an OMM 
protein containing a LIR motif has been shown to act as a mitochondria receptor 
under hypoxia by binding LC3 and enabling engulfment of mitochondria by the 
autophagosomes [41]. FUNDC1 is an integral OMM protein, which becomes post-
translationally modified under stress conditions stimulating mitophagy, thus enabling 
FUNDC1 to function as mitophagic receptor.  For example upon mitophagy induction 
by hypoxia or mitochondrial uncouplers, ULK1 is upregulated and localizes to 
fragmented mitochondria, where it phosphorylates FUNDC1 at serine 17, hereby 
increasing its binding to autophagosome-associated LC3 [42].  
The role of FUNDC1 in mitophagy has still has to be confirmed in vivo, since 
its function has only been addressed in cellular models. In this context, it would be 
interesting to investigate the role of FUNDC1 during development and under 
pathological conditions in which removal of ROS-producing mitochondria has been 
shown to play a major role, like ischemia-reperfusion, neurodegenerative diseases 
and cancer.  
c) BNIP3 and NIX regulated mitochondrial clearance 
BNIP3 and NIX, are two BCL2 family members that contain an atypical BH3-
only domain and a C-terminal transmembrane domain, essential for their 
homodimerization and mitochondrial localization [43]. BNIP3 and BNIP3L/NIX 
(thereafter named NIX) were first recognized for their role in the regulation of 
mitochondrial apoptosis [44-46]. However, recent studies suggest that BNIP3 and 
NIX rather than directly promoting cell death, regulate mitochondrial fragmentation 
and mitophagy by establishing interactions with different mitochondrial proteins. The 
expression of BNIP3 and NIX is strongly upregulated by the transcriptional activation 
of the hypoxia-inducible factor (HIF-1) [43] [47], induced by hypoxia, malignant 
transformation [48]  or even chemotherapeutics e.g. doxorubicin [49].  
Recently, key molecular mechanisms through which BNIP3 and NIX regulate 
mitochondrial clearance have been elucidated. Interestingly, some of these 
mechanisms are common while others are unique for one of the two proteins, 
suggesting that upstream regulators of these pro-autophagic proteins may utilize 
BNIP3 or NIX in a context and possibly stress specific manner.  
A well described mechanism by which BNIP3 mediates mitophagy induction entails 
the binding of its BH3-domain with BCL2, hereby scavenging BCL2 away from 
Beclin1, resulting in the release of the pro-autophagic activity of Beclin1 [50] (Fig. 1 
and Fig. 2). Additionally, BNIP3 can activate the autophagic machinery via direct 
binding and inhibition of Rheb, a Ras related small GTPase and key upstream 
activator of mTORC1 [51]. A more direct mechanism enabling mitophagy induction, 
involves a role for BNIP3 as mitochondrial receptor. BNIP3 can associate with the 
OMM and interact with LC3/ LC3 like proteins through its LIR domain [52, 53] (Fig. 2). 
The interaction of BNIP3 with the LC3 family members, LC3B or GATE-16, has been 
shown to be enhanced by phosphorylation of the serine residues 17 and 24 flanking 
the BNIP3 LIR domain [53]. Interestingly, induction of mitophagy in cardiac myocytes 
by overexpression of BNIP3 was independent of mitochondrial Ca2+ uptake, ROS 
generation and opening of the permeability transition pore, mitochondria-regulated 
processes that can instigate their fragmentation [54]. 
Interestingly, mitochondria-localized BNIP3 has been shown to impair mitochondrial 
respiration by inducing the degradation of components of the electron transfer chain 
through mitochondrial proteases, a process stimulating the removal of mitochondria 
through mitophagy [55].  
In adult cardiac myocytes, BNIP3 favors the translocation of PARKIN at the 
mitochondria in a Drp1-dependent manner, a cytoprotective process that promotes 
Drp1-mediated mitochondrial fission and PARKIN-regulated degradation of unhealthy 
mitochondria [26] (Fig. 2).  
A functional connection between BNIP3 and mitochondrial clearance has been 
suggested under different physiopathological conditions and observed in several 
tissues. For example, using rat or mouse models BNIP3 has been linked to the 
induction of mitophagy after acute kidney injury in renal tubular cells [56], in aged 
kidneys [57], after acute spinal cord injury [58], during skeletal muscle atrophy [59], in 
the diaphragm after chronic hypoxia [60], in the liver especially under fasting 
conditions [61] as well as in tumor-associated fibroblasts [62]. This suggests a rather 
widespread and important role for BNIP3 in the regulation of mitochondria 
degradation induced by a variety of endogenous and exogenous cellular insults. 
Also for NIX several mechanisms for mitophagy induction have been described. In 
analogy to BNIP3, NIX can induce the autophagic machinery either by releasing 
Beclin1 [50], or by increasing mitochondrial ROS production after CCCP-treatment, 
leading to the inhibition of mTORC1 signaling. NIX also functions as a LIR-containing 
mitochondrial receptor [63-65] and can contribute to mitochondrial priming by 
controlling the mitochondrial localization of PARKIN [27]. Scattered evidence exists 
delineating the connections between PINK1-PARKIN pathway and the BNIP3/NIX 
regulation of mitophagy [26, 27], but the exact mechanism underlying their interaction 
is still obscure and requires further study. Another level of mitophagy regulation was 
recently found by Li and coworkers, who showed that both FUNDC1 and NIX levels 
are down-regulated by the hypoxia-responsive microRNA-137 (miR-137), which 
when overexpressed inhibits hypoxia-induced mitochondria clearance without 
impairing global autophagy [66]. Thus reduction of miR-137 under hypoxia, allowing 
the increase of NIX and FUNCD1 bound to LC3, may represent a mechanism 
regulating mitophagy, while leaving general autophagy unrestrained.  
Although in most studies mitochondrial degradation has been linked to the removal of 
superfluous or damaged mitochondria, a recent report links energetic status of 
mitochondria with NIX-mediated mitophagy.  Conditions stimulating increased 
oxidative phosphorylation in HeLa cells, induced by switching glucose to glutamine 
as primary carbon source for ATP production, were found to be associated with 
heightened mitophagy. Mitophagy mediated by stimulated oxidative phosphorylation, 
was independent on mTORC1, but required the recruitment of Rheb to the 
mitochondria through a NIX-dependent mechanism and the formation of a Rheb-NIX-
LC3 complex [67]. Although the signaling mechanism by which NIX mediates the 
recruitment of Rheb to mitochondria is still elusive, the local induction of hypoxia 
generated by the increased rate of mitochondrial oxygen consumption was 
suggested as a potential triggering signal. Irrespective of the exact molecular 
mechanism, NIX-mediated mitophagy was found to be vital for the maintenance of 
maximal respiration and ATP production. This suggests that this pathway sensing the 
energetic status of the mitochondria, is activated to preserve cellular bioenergetic 
efficiency, by ensuring the renewal of a healthy mitochondrial pool and preventing the 
accumulation of damaged mitochondria [67]. Why this process is selective for NIX is 
not yet clear, as BNIP3 is also hypoxia-responsive and shares with NIX the ability to 
directly interact with Rheb. 
In vivo NIX has been shown to be essential for the recruitment of 
LC3/GABARAP pro-autophagic proteins to the mitochondria during mitophagy in 
maturing murine erythrocytes [64] and it has been linked to the induction of 
mitophagy after acute spinal cord injury in rats [58].  
All together these studies indicate that BNIP3 and possibly NIX, regulate 
different signaling mechanisms that either precede mitochondrial clearance (i.e. 
Drp1-mediated fission of the mitochondrial network) or act directly at the core of the 
mitophagy machinery, by modulating degradative processes (i.e. activation of 
mitochondrial proteases), acting as a mitophagy receptor (via LIR domain) or 
inducing the translocation of pro-mitophagic mitochondrial complexes (i.e. PARKIN). 
 
 
4. Autophagy, mitophagy and cancer 
Metabolic stress present within the tumor microenvironment principally nutrient 
deprivation and hypoxia, have been reported to induce autophagy in cancer cells and 
the surrounding stroma [68]. In agreement with this, autophagy in tumors is found 
particularly heightened in hypoxia areas, where energy and nutrient demand are 
higher and stress adaptation is a pre-requisite for cancer cells to survive.  
However, while the pro-survival function of autophagy may enable cancer cells to 
adapt to a hostile environment and resist cancer therapy, emerging evidence 
supports a highly dynamic and context dependent role for autophagy in cancer [69, 
70]. In early stages of tumorigenesis, damage mitigation by autophagy serves as a 
tumor suppressor mechanism, limiting ROS-driven genomic instability and preventing 
necrosis-associated inflammation [71-73].  
Moreover, by removing damaged mitochondria in conditions of stress, mitophagy 
prevents the accumulation of toxic ROS, which may propagate damage to other 
macromolecules and the nucleus [74-76]. Additionally given that mitochondrial DNA 
mutations are also incited by mitochondria ROS production, mitophagy may be a 
mechanism to decrease the rate mtDNA mutations, which may be further propagated 
to daughter cells and could contribute to cancer progression [77].  In more advanced 
tumors, autophagy provides energy for accelerated tumor cell growth and helps 
tumor cells to withstand metabolic stress [71, 72, 78].   
Moreover, the dynamic and contextual role of autophagy in cancer appears to be 
closely linked to the genetic landscape of the developing tumors, as recently shown 
in a mouse model of pancreatic ductal adenocarcinoma, where the pro-tumorigenic 
role of autophagy was dependent on the presence of tumor suppressor p53 [79].  
Recent studies indeed disclose that aggressive tumors driven by activating Ras 
mutations [80, 81]), such as pancreatic and lung cancer, are particular reliant on 
autophagy to support energy metabolism, cell growth and viability in nutrient-
deprived conditions [82-85]. Using genetically engineered mouse models of 
KRasG12D-driven non–small cell lung carcinoma, the genetic ablation of autophagy 
was shown to convert aggressive adenomas and adenocarcinomas into benign 
tumors (oncocytomas). These tumors displayed an accumulation of dysfunctional 
mitochondria suggesting that mitophagy contributed to cancer progression in this 
Ras-driven lung cancer model [79]. Similar findings were recently confirmed in lung 
tumors harboring activating mutations of BRAF [86], a downstream effector of Ras 
and activator of the ERK-pathway whose oncogenic BRAFV600E variant is 
expressed in a variety of cancers. Hence, this ‘autophagy addiction’ may be a 
characteristic of aggressive human cancers. Moreover in this BRAFV600E-driven 
lung cancer model the tumor-suppressive function of autophagy are largely explained 
by the preservation of redox homeostasis early in tumorigenesis, whereas later 
during cancer progression maintenance of mitochondrial clearance is essential to 
supply essential metabolic substrates, like glutamine, to feed mitochondrial function 
and to confer cancer cell’s fitness and growth [86]. 
Which components of the mitophagy pathway(s) and signaling mechanisms are 
implicated in the pro-tumorigenic function of autophagy remain to be characterized, 
although it can be hypothesized that hypoxic-responsive NIX/BNIP3 and Ras-
regulated BNIP3 [87] may be critical molecular candidates. This notion seems to be 
particular relevant for melanoma, the most recurrent BRAFV600E-driven malignancy, 
for which the relevance of autophagy and BNIP3-mediated mitochondrial quality 
control mechanisms are emerging.  
 
5. Relevance of autophagy and mitophagy in melanoma 
Cutaneous malignant melanoma (hereafter referred to as melanoma) is a 
cancer originating from the melanocytes, the pigment producing cells that reside in 
the epidermis of the skin. Despite numerous health campaigns for early diagnosis 
and protection, melanoma is the most rapidly increasing cancer in the white 
populations [88]. If melanoma is diagnosed in the early stages (radial growth phase) 
it can be cured by surgical resection. However, metastatic melanoma is largely 
refractory to existing therapies and has a very poor prognosis, with a median survival 
rate of 6 months and 5-year survival rate of less than 5% [89]. Like many other 
cancers, melanoma is the result of the interplay between environmental and genetic 
components, (readers are referred to a recent review on the genetic landscape of 
melanoma [90]). 
 
a) Deregulation of autophagy pathways during melanomagenesis 
The first clues indicating a deregulation of autophagy during 
melanomagenesis were already found in the early 1980s, when pathologists 
described the presence of giant autophagic melanosomes complexes in malignant 
melanoma [91]. Despite the early recognition of the involvement of autophagy in 
melanoma, only a limited amount of studies have investigated the alterations in the 
autophagic status of the cells during melanomagenesis.  
In benign nevi autophagy has been reported to be increased to support 
oncogene-induced senescence (e.g. driven by BRAFV600E expression) [92, 93]. 
However during the early stages of malignant transformation autophagy is decreased 
as compared to benign nevi [92, 94] and melanocytes [95]. In metastatic melanoma 
along with the acquisition of other mutations altering the oncogenic landscape, the 
autophagy capacity is re-established to support cancer cell’s high metabolic 
demands and survival in the face of the stressful tumor microenvironment [95-98]. 
Thus these studies indicate that melanoma progression is coupled to alterations in 
the amount of autophagosomes as well as pro-autophagic proteins, supporting a 
dynamic role for autophagy in melanoma progression (see Fig. 3).  Importantly, a 
high level of autophagy in melanoma patient’s tumors is associated with a lower 
therapeutic response and a worse outcome, further supporting the relevance of 
autophagy as possible prognostic marker and suggesting autophagy as a therapeutic 
target in melanoma [85, 96]. 
Despite its increasing relevance in cancer, mitophagy is a virtually 
unexplored field in melanoma [99]. However the existing data, combined with the 
importance for mitochondria in redox control, metabolism and cell death hint towards 
an important role for mitophagy in melanomagenesis and melanoma progression. 
Indeed exposure to sunlight, one of the main risk factors for melanoma, which has 
been reported to induce mitochondrial DNA mutations/deletions, has been recently 
shown to induce changes in mitochondrial morphology and mitophagy in 
melanocytes [100]. This suggests that functional mitophagy in the melanocytes is 
required to maintain mitochondrial quality and as a mechanism preventing 
melanocyte transformation. These studies suggest that expression levels of pro-
mitophagic proteins during melanomagenesis could allow the identification of novel 
biomarkers of melanoma progression [101], a premise that deserves to be validated 
in future studies. 
 
b) Metastatic melanoma are addicted to autophagy and mitochondrial quality 
control   
Recent studies delineate a crucial role for autophagy in metastatic melanoma. Marino 
et al showed that under mildly acid cell culture conditions, the number of 
autophagosomes is rapidly increased and inhibition of autophagy via knockdown of 
Atg5 reduces melanoma cell survival [102]. In the same line Sheen and co-workers, 
reported that a leucine-free diet combined with an autophagy inhibitor, synergistically 
reduced the growth of xenografted human melanoma tumors and induced 
widespread apoptosis of the cancer cells [103]. However, even under nutrient-rich 
growth conditions metastatic melanoma cells display an addiction to autophagy. This 
is supported by data from several groups who reported that pharmacologic inhibition 
of autophagy or knockdown of key autophagy genes (e.g. Beclin1 and Atg7) in 
melanoma induces spontaneous melanoma cell death [104] [105]. Recent data from 
our group show that inhibition of mitophagy through BNIP3 knockdown or blockage of 
autophagic flux though chloroquine (CQ) or Atg5 silencing, increased similarly 
spontaneous cell death and reduced the clonogenic expansion of metastatic 
melanoma cells in vitro [106]. Intriguingly, loss of melanoma clonogenic growth under 
autophagy/mitophagy inhibition was coupled to an increased ROS production and a 
metabolic shift from oxidative phosphorylation towards glycolysis (Maes et al, 
unpublished data). These observations highlight that metastatic melanoma rely on 
mitophagy to maintain the functional pool of mitochondria required to support their 
high metabolic demands ([106] and Maes et al., unpublished data).  Impairing this 
BNIP3-regulated process ultimately compromised their ability to survive, by 
instigating a redox and bioenergetic failure, a conjecture that needs to be further 
validated in vivo by deleting BNIP3 in melanoma cells. Whether the NIX-Rheb 
pathway described before [67] also contributes to the modulation of mitochondria 
bioenergetics and growth in melanoma requires further studies. The observation that 
inhibitors of farnesylation, a post-translational modification that is required for the 
mitochondria anchorage of Rheb to ensue mitophagy [107], reduces melanoma cell 
growth in vitro, supports further studies aiming at revealing this connection. 
Moreover, given the additional, mitophagy-independent role of BNIP3 in 
preserving the architecture of actin-cytoskeleton and CD47 levels in metastatic 
melanoma [106], BNIP3 deficiency has the potential to impact both melanoma cell 
intrinsic (metabolism, redox signaling, migration, adhesion) and extrinsic (cell-cell 
interactions, phagocytosis, immunosurvelliance) features. Interestingly increased 
transcript-expression levels BNIP3 tend to correlate with reduced overall survival in a 
melanoma patient cohort [106], thus suggesting that BNIP3 may become an 
interesting therapeutic target in melanoma.  
Besides harboring heightened basal levels of autophagy, various anti-
melanoma therapeutic regimens have been shown to stimulate autophagy with a 
predominant cytoprotective function [68], thus suggesting that interfering with 
autophagy may ameliorate their therapeutic effects. For example, Lotze et al found 
that interleukin-2 therapy induces massive autophagy activation, which when 
inhibited with the lysosomotropic drug CQ ameliorated therapeutic outcome. in line 
with this treatment of different melanoma cell lines with the mTORC1 inhibitor 
temsirolimus, induced pro-survival autophagy and the combination of temsirolimus 
with CQ treatment significantly increased therapy response [104]. This finding is 
interesting as in a phase I clinical trial assessing the potential temsirolimus in 
combination with the CQ derivative hydroxychloroquine (HCQ) 73% of patients with 
metastatic melanoma showed stabilized tumor growth, as compared to temsirolimus 
treatment alone, which failed to stabilize the disease [108]. Interestingly Haq et al 
reported that melanoma cells become addicted to oxidative phosphorylation after 
treatment with inhibitors of BRAFV600E, targeting the most common genetic 
alteration in melanoma. The increased oxidative phosphorylation after BRAFV600E 
inhibition is driven by the activation of MITF, that augments the expression of 
transcription factor PPARγ co-activator 1α (PGC-1α), resulting in increased 
expression of genes involved in citric acid cycle and oxidative phosphorylation [109]. 
Importantly up to 30% of melanoma harbor genomic amplifications of  MITF, which 
drives PGC1α overexpression, leading to increased mitochondrial phosphorylation 
and capacity for reactive oxygen species detoxification, hereby  increasing survival 
under oxidative stress conditions [110]. Interestingly PGC1α has been reported to co-
activate the expression of TFEB, a promoter of the expression of genes in the 
autophagy pathway as well as genes required for lysosome biogenesis and function 
[111], suggesting a role for autophagy in the prosurvival activities of the MITF-PGC-
1α axis. Indeed Ma et al reported that after BRAFV600E inhibition, autophagic flux 
was increased and therapeutic response was ameliorated when the mice where co-
treated with the autophagy inhibitor Lys-05 [112]. Taken together these results 
support a model whereby melanoma cells displaying high MITF activity depend on 
oxidative phosphorylation for ATP production and concomitantly become addicted to 
mitophagy to maintain a functional pool of mitochondria. Another piece of the puzzle 
was provided by Armstrong et al, who reported that BRAFV600E-melanoma cells 
become resistant to mTORC1-mediated autophagy induction (e.g. via rapamycin, 
fenretinide or bortezomib), hereby limiting the therapeutic advantage of autophagy 
inhibition [113, 114].  
Taken all together, these data suggest that the outcome of melanoma patients 
harboring wild type BRAF following anticancer therapy may be ameliorated by the 
combination with an autophagy blocker. On the other hand, in case of those patients 
expressing the BRAFV600E mutant, autophagy blockers will only be effective when 
combined with a BRAFV600E inhibitor, indicating a prognostic role for BRAF mutant 
status for the efficacy of autophagy-blocking therapies. 
The encouraging preclinical activities support the use of CQ/HCQ as first-
generation autophagy blockers in combination with anti-cancer treatments. 
Importantly, the ability of CQ to inhibit the autophagic removal of damaged cellular 
materials may not be the only mechanism by which CQ exerts its anti-cancer action, 
since by blocking lysosomal degradation, this lysosomotropic agent could have anti-
cancer effects that are independent on autophagy blockage. Additionally systemic 
treatment with autophagy blockers not only affects the cancer cells, but also the 
tumor stroma cells, important players in tumor progression and therapy response. 
Indeed recent in vitro data [115] and our recent in vivo data (Maes et al, under 
revision) indicate that the effects of cannot be completely reproduced by silencing 
key autophagy genes like Atg5 or Atg7 and that CQ also alters the tumor stromal 
compartment. Our systematic analysis of the effects of the systemic delivery of 
chloroquine or targeted inhibition of cancer cell-intrinsic autophagy, via shRNA-
mediated knockdown of Atg5 in cancer cells, in mouse models of melanoma revealed 
that CQ, besides inhibiting melanoma-intrinsic autophagy, also ‘normalized’ the 
highly disorganized tumor vasculature. CQ increased tumor vessels tightening and 
perfusion, hereby ameliorating tumor perfusion and reducing tumor cell intravasation 
and metastasis (Maes et al, under revision). Instead, Atg5-/- tumors displayed no 
vascular changes and increased necrosis. Moreover, in sharp contrast with the 
vasculo-normalizing effects of CQ, melanomas grown in mice with endothelial cell-
specific ablation of Atg5 displayed an even more abnormal vasculature, thus 
indicating that CQ ameliorates the tumor vasculature through mechanisms that are 
autophagy-independent. Intriguingly, we found that CQ caused a stimulation of 
Notch1 signaling, by interfering with its endocytic trafficking, which was found 
responsible for the vessel normalizing effects observed in CQ-treated tumors (Maes 
et al, under revision). This study thus delineates novel and important assets of CQ in 
anti-cancer treatment, as this agent appears to be capable of targeting cancer cell-
intrinsic prosurvival autophagy, while reinforcing cancer-cell extrinsic barriers, like a 
more impenetrable endothelial cell barrier and tumor oxygenation, crucial to fend off 
tumor dissemination and improve chemo/radiotherapy responses.  
 
6. Concluding remarks 
Although the molecular and signaling mechanisms of mitophagy in mammalian cells 
still need to be completely elucidated, selective mitochondrial degradation is 
emerging as a key process involved in mitochondrial quality control and regulating 
crucial mitochondrial functions like cellular redox control and bioenergetics. 
Moreover, accumulating evidence is unraveling the critical role of this autophagy 
pathway in supporting energy metabolism and growth of cancer cells. Several 
outstanding questions remain to be answered including how mitochondria are 
selected for degradation in physiological and pathological conditions, the impact that 
their removal has for metabolic reprogramming and stress adaptation and how 
mitochondrial degradation affect the interface between cancer cells and their 
environment. Certainly these unanswered questions will provide a great incentive to 
further study the role of key autophagy pathways as mitophagy in dreadful human 
pathologies, like melanoma. 
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  Figure 1: Molecular signaling during autophagy. The figure schematically depicts 
the different stages of autophagy and their major molecular regulators. Vesicle 
nucleation, is controlled by the ULK1-Atg13-Atg101-FIP200 complex which is 
negatively regulated by the mTORC1 complex. Upon autophagy activation, mTORC1 
dissociates from the ULK complex, leading to ULK1/2 and Atg13 dephosphorylation 
and translocation of the complex to the autophagosomes formation site. Autophagy 
activation by reduced cellular energy occurs through the AMP-activated protein 
kinase (AMPK), which phosphorylates Raptor, hereby inhibiting mTOR. Upon 
activation, the ULK-complex is involved in the correct localization of the Beclin1-
VPS34-Atg14L-P150 complex, whose activity is positively regulated by Bif-1, 
UVRAG, Rab5 and AMBRA1 or inhibited by Bcl2 and Rubicon. Upon autophagy 
activation, ULK1 phosphorylates Ambra1, releasing the PI3K3 complex from the 
cytoskeleton and enabling the relocalization of this complex to the ER. Vesicle 
elongation, is mediated by two-ubiquitin-like conjugation systems. Firstly, Atg5 
conjugates to Atg12 assisted by Atg7 and Atg10 (E-1 and E-2 like enzymes, 
respectively). The Atg5-Atg12 conjugate binds to Atg16L forming the Atg16L 
complex, which transiently associates to the growing autophagosomes and leaves 
the autophagosomes after closure. The second ubiquitin-like conjugation system 
involves LC3 (microtubules-associated light chain-3), which is cleaved by the 
cysteine protease Atg4 to produce LC3-I. Its glycine residue conjugates to 
phosphatidylethanolamine (PE) with the assistance of Atg7, the E2-like enzyme Atg3 
and the Atg16L complex to produce the lipidated autophagosomal-localized LC3-II. 
Autophagolysosome formation. Rab7 promotes microtubule transport and fusion 
of the autophagosomes with the lysosomes. Recycling. After autophagolysosome 
formation LC3-II located at the cytosolic surface of the autophagosolysosome 
undergoes Atg4-mediated decoupling from PE to be recycled.  
 
 
Figure 2. Signaling mechanisms in mitochondria priming.  
A) In unstressed, healthy conditions PINK1 is imported into the OMM, IMM and 
mitochondrial matrix via the TOM and TIM23 complexes. Following import in the 
mitochondria PINK1 is cleaved by MPPs in the matrix and by the mitochondrial 
intramembrane protease PARL localized in the IMM, hereby generating an N-terminal 
destabilizing amino acid. The cleavage product is subsequently translocated into the 
cytosol, where it is degraded by the proteasome, thus guaranteeing constant low 
levels of mitochondrial PINK1 under basal conditions. B) When mitochondrial 
membrane potential is lost or unfolded proteins accumulate in the mitochondrial 
matrix PINK1 is no longer imported in the IMM and mitochondrial matrix, but is 
stabilized on the OMM, resulting in the recruitment of the E3 ubiquitin ligase PARKIN 
from the cytosol to the damaged mitochondria. Upon recruitment to the mitochondria 
PARKIN polyubiquitinates several mitochondrial proteins, which recruit ubiquitin-
binding LIR-containing adaptors, like p62/SQSTM1 and NBR1, resulting in the 
incorporation of the damaged mitochondria into the LC3-containing 
autophagosomes. The size of the autophagosomes is restricted by the RAB 
GTPases deactivators TBC1D15 and TBC1D17 in concert with Fis1 and LC3 
homologue proteins by controlling by coordinating the activity of the small GTPase 
Rab7. C) During hypoxia or mitochondrial depolarization FUNDC1, an OMM protein 
containing a LIR motif is phosphorylated by ULK1, hereby enabling it as a 
mitochondrial receptor. D) Under hypoxia BNIP3 and NIX are upregulated 
downstream of HIF-1. BNIP3 induces the autophagic machinery by freeing the pro-
autophagic protein Beclin1 from Bcl2 or via direct binding and inhibition of Rheb a 
key upstream activator of mTOR. BNIP3 also functions mitochondrial receptor as it 
can associate with the mitochondrial outer membrane and interact with LC3/ LC3 like 
proteins through its LIR domain. Additionally BNIP3 favors mitophagy by promoting 
the translocation of DRP1, a fission promoting protein to the mitochondria. Also NIX 
can induce the autophagic machinery via the disruption of the interaction between 
Bcl2 and Beclin1 or by increasing mitochondrial ROS production, hereby inhibiting 
mTOR signaling. In analogy to BNIP3, NIX functions as a LIR-containing 
mitochondrial receptor. During mitophagy induced by increased oxidative 
phosphorylation, NIX is essential for the recruitment of Rheb to the mitochondria, 
hereby preventing the accumulation of damaged mitochondria. For a more detailed 
description and abbreviations see text. 
 
 Figure 3: Autophagy deregulation during melanomagenesis 
Abbreviations: BM: basal membrane 
For more details and references see text. 
	  
